



NCTN Brain Cancer Trials Portfolio (Open as of 1/15/2026)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



Cross-disease trials:



NCTN Brain Cancer Trials (Open as of 1/15/2026)

| Protocol Number | Phase | Protocol Title |
|------------------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A071401 | II | Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations |
| A071701 | II | Genomically-Guided Treatment Trial in Brain Metastases |
| A072201 | II | Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent Glioblastoma |
| CCTG CE.7 | III | A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases |
| EAF223 | II | Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE) |
| NRG-BN003 | III | Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma |
| NRG-BN011 | III | A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma |
| NRG-BN013 | III | Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases |
| NRG-BN014 | III | A Phase III Randomized Clinical Trial of Proton Craniospinal Irradiation Versus Involved-Field Radiotherapy for Patients with Breast Cancer or Non-Small Cell Lung Cancer Leptomeningeal Metastasis (Radiate-LM) |
| EAY191 | Other | Molecular Analysis for Combination Therapy Choice (ComboMATCH) |
| EAY191-E5 | II | A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial |
| EAY191-N5 | II | A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial |